当前位置:首页 > 医学进展 > 肿瘤 > 正文

[2016BOA视频]黄慧强教授对淋巴瘤的三个重要研究进行评述

2016年6月24-25日,临床肿瘤学新进展学术研讨会——Best of ASCO Event in China2016在杭州召开。24日上午的淋巴瘤专场上,中山大学附属肿瘤医院大内科主任、血液研究所所长黄慧强对淋巴瘤的三个重要研究进行了评述。


三项研究摘要编号和题目:

Abstract 7504:Randomized phase III study onthe effect of early intensification of rituximab in combination with 2-weeklyCHOP chemotherapy followed by rituximab or no maintenance in patients withdiffuse large B-cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study.

 

Abstract 7503:Two years rituximab maintenancevs. observation after first line treatment with bendamustine plus rituximab(B-R) in patients with mantle cell lymphoma: First results of a prospective,randomized,multicenter phase 2 study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial).

 

Abstract 7506:PILLAR-2: A randomized,double-blind, placebo-controlled, phase 3 study of adjuvant everolimus (EVE) inpatients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL).


直通车:张会来教授分享三项淋巴瘤重要研究


会议专题》》》2016临床肿瘤学新进展学术研讨会(BOA)

 

阅读次数:  

发表评论